You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 17, 2024

Claims for Patent: 11,124,526

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,124,526

Title:	Crystalline beta-lactamase inhibitor
Abstract:	A crystalline compound of formula (I):
Inventor(s):	Lamonica Alessandro, Forzatti Marco, Biondi Stefano
Assignee:	Allecra Therapeutics SAS
Application Number:	US16177406
Patent Claims:	2. A crystalline compound according to claim 1 , with an XRPD spectrum substantially as shown in .3. A crystalline compound according to claim 1 , the compound having a Thermo Gravimetric Analysis (TGA) curve showing an endothermic event at about 163° C.±2° C.4. A crystalline compound according to claim 1 , the compound having a Differential Scanning calorimetry (DSC) curve showing an endothermic event at about 163° C.±2° C.6. A crystalline compound according to claim 5 , the compound having an XRPD spectrum substantially as shown in .7. A crystalline compound according to claim 5 , the compound having a Thermo Gravimetric Analysis (TGA) curve showing an endothermic event at about 155° C.±2° C.8. A crystalline compound according to claim 5 , the compound having a Differential Scanning calorimetry (DSC) curve showing an endothermic event at about 180° C.±2° C.10. A crystalline compound according to claim 9 , the compound having an XRPD spectrum substantially as shown in .11. A crystalline compound according to claim 9 , the compound having a Thermo Gravimetric Analysis (TGA) curve showing an endothermic event at about 160° C.12. A crystalline compound according to claim 9 , the compound having a DSC profile showing an exothermic peak at approximately 184° C.14. A method of treating a bacterial infection comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline compound according to .15. A method of treating a bacterial infection comprising co-administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a crystalline compound according to and a therapeutically effective amount of an antiobiotic.16. The process according to claim 13 , wherein crystals are allowed to form from the solution for more than four hours before separation of crystals from the solvent.17. The process according to claim 13 , wherein crystals are allowed to form from the solution for at least six hours before separation of crystals frorm the solvent.18. The process according to claim 17 , wherein the temperature of the solution is reduced while the crystals are allowed to form.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.